Even more effective analogues, such as tirzepatide, the first glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist (or twincretin), and combination semaglutide-cagrilintide, show promise in achieving improved glycaemic control and weight loss
If they qualify, a licensed provider prescribes the right medication, and the patient receives it via home delivery each month
India's massive 1.4B+ population, rising #metabolic #disorders (third-largest overweight population globally), and price-sensitive market make this a game-changer: GLP-1 therapies could explode from ~1,000 crore to 5,000 crore+ by 2030, with bundled clinics, telehealth, and diagnostics scaling fast
GHK-Cu has been the subject of over 100 published studies spanning five decades of research, and the vast majority of that literature examines GHK-Cu as a single compound